Heron Therapeutics, Inc. (HRTX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Heron Therapeutics (HRTX) Q1 2026: IGNITE 2.0 Expands Targeted Accounts by 38%, Setting Up Recovery
May 11, 2026
-
Heron Therapeutics (HRTX) Q4 2025: Acute Care Franchise Surges 57% as Commercial Expansion Accelerates
February 27, 2026
-
Heron Therapeutics (HRTX) Q3 2025: Acute Care Net Sales Jump 49% as Zynrelef Momentum Accelerates
November 04, 2025
-
Heron Therapeutics (HRTX) Q2 2025: Acute Care Franchise Grows 55%, Restructuring Targets Second-Half Acceleration
August 12, 2025